Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Substantiated Cases by Year
Novartis Substantiated Cases: 745 in FY2025, down 19.1% from a year earlier.
Latest, FY2025
745
Period ended Dec 31, 2025
Change on a year earlier
-19.1%
921 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
“| Higher-risk allegations substantiated | 745 | 921 | ∆ | 38, 39 |”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Substantiated Cases | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 745 | -19.1% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 921 | +106.0% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 447 | +87.0% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2022 | Dec 31, 2022 | 239 | – | Novartis Form 6-K (0001370368-25-000008) ↗ |
Cite this data
StockData. (2026). Novartis Substantiated Cases, annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/gov-allegations-substantiated
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.